Drug Profile
Research programme: siRNA therapeutics - Pfizer/Arbutus Biopharma
Alternative Names: RNAi therapeutics - Arbutus Biopharma/Pfizer; Small interfering RNA therapeutics - Arbutus Biopharma/PfizerLatest Information Update: 04 Apr 2018
Price :
$50
*
At a glance
- Originator Pfizer; Tekmira Pharmaceuticals Corporation
- Developer Arbutus Biopharma; Pfizer
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Mar 2018 Arbutus has issued and pending patents for its therapeutic HBV product candidates and LNP delivery technology in countries worldwide
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada (Parenteral)
- 16 Mar 2010 Early research in Undefined indication in Canada (Parenteral)